<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
    <link rel="stylesheet" href="../css/uswds.min.css">
    <link rel="stylesheet" href="../css/style.css">
    <link rel="stylesheet" href="css/uswds.min.css">
    <link rel="stylesheet" href="css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR522.html">Part 522
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 522.1145  Hyaluronate.
                            </h3>
                            <p class="depth0"><em>(a)(1)</em> Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.</p><p class="depth0"><em>(1)</em> Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.</p><p class="depth0"><em>(2)</em> Sponsor. See 054771 in Sec. 510.600(c).</p><p class="depth0"><em>(3)</em> Conditions of use--(i) Amount. Small and medium-size joints (carpal, fetlock): 20 mg; larger joint (hock): 40 mg. Treatment may be repeated at weekly intervals for a total of three treatments.</p><p class="depth0"><em>(ii)</em> Indications for use. Treatment of joint dysfunction in horses due to noninfectious synovitis associated with equine osteoarthritis.</p><p class="depth0"><em>(iii)</em> Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p><p class="depth0"><em>(b)(1)</em> Specifications. Each milliliter of sterile aqueous solution contains 5 milligrams of hyaluronate sodium.</p><p class="depth0"><em>(1)</em> Specifications. Each milliliter of sterile aqueous solution contains 5 milligrams of hyaluronate sodium.</p><p class="depth0"><em>(2)</em> Sponsor. See 054771 in Sec. 510.600(c) of this chapter.</p><p class="depth0"><em>(3)</em> Conditions of use--(i) Amount. Small and medium-size joints (carpal, fetlock): 10 mg; larger joint (hock): 20 mg. Treatment may be repeated at weekly intervals for a total of four treatments.</p><p class="depth0"><em>(ii)</em> Indications for use. Treatment of joint dysfunction in horses due to noninfectious synovitis associated with equine osteoarthritis.</p><p class="depth0"><em>(iii)</em> Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p><p class="depth0"><em>(c)(1)</em> Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.</p><p class="depth0"><em>(1)</em> Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.</p><p class="depth0"><em>(2)</em> Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.</p><p class="depth0"><em>(3)</em> Conditions of use--(i) Amount. Small and medium-size joints (carpal, fetlock): 20 mg. Treatment may be repeated after 1 or more weeks but not to exceed 2 injections per week for a total of 4 weeks.</p><p class="depth0"><em>(ii)</em> Indications for use. For the intra-articular treatment of carpal or fetlock joint dysfunction in horses due to acute or chronic, non-infectious synovitis associated with equine osteoarthritis.</p><p class="depth0"><em>(iii)</em> Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p><p class="depth0"><em>(d)(1)</em> Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.</p><p class="depth0"><em>(1)</em> Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.</p><p class="depth0"><em>(2)</em> Sponsor. See 000061 in Sec. 510.600(c) of this chapter.</p><p class="depth0"><em>(3)</em> Conditions of use--(i) Amount. 50 milligrams in carpal and fetlock joints.</p><p class="depth0"><em>(ii)</em> Indications for use. For treatment of equine carpal and fetlock joint dysfunction caused by traumatic and/or degenerative joint disease of mild to moderate severity.</p><p class="depth0"><em>(iii)</em> Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p><p class="depth0"><em>(e)(1)</em> Specifications. Each milliliter of solution contains:</p><p class="depth0"><em>(1)</em> Specifications. Each milliliter of solution contains:</p><p class="depth0"><em>(i)</em> 10 milligrams (mg) hyaluronate sodium; or</p><p class="depth0"><em>(ii)</em> 10 mg hyaluronate sodium with benzyl alcohol as a preservative.</p><p class="depth0"><em>(2)</em> Sponsors. See sponsors in Sec. 510.600(c) of this chapter:</p><p class="depth0"><em>(i)</em> No. 050604 for use of products described in paragraph (e)(1) as in paragraph (e)(3) of this section.</p><p class="depth0"><em>(ii)</em> No. 017030 for use of product described in paragraph (e)(1)(i) as in paragraph (e)(3) of this section.</p><p class="depth0"><em>(3)</em> Conditions of use--(i) Amount. 20 mg of the product described in paragraph (e)(1)(i) of this section by intra-articular injection into the carpus or fetlock; or 40 mg of the product described in paragraph (e)(1)(i) or (e)(1)(ii) of this section by slow intravenous injection into the jugular vein. Treatment may be repeated at weekly intervals for a total of three treatments.</p><p class="depth0"><em>(ii)</em> Indications for use. For treatment of carpal or fetlock joint dysfunction due to noninfectious synovitis associated with equine osteoarthritis.</p><p class="depth0"><em>(iii)</em> Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p><p class="depth0"><em>(f)(1)</em> Specifications. Each milliliter of sterile aqueous solution contains 11 milligrams of hyaluronate sodium.</p><p class="depth0"><em>(1)</em> Specifications. Each milliliter of sterile aqueous solution contains 11 milligrams of hyaluronate sodium.</p><p class="depth0"><em>(2)</em> Sponsor. See 060865 in Sec. 510.600(c).</p><p class="depth0"><em>(3)</em> Conditions of use--(i) Amount. Small and medium-size joints (carpal, fetlock): 22 mg; larger joint (hock): 44 mg. Treatment may be repeated at weekly intervals for a total of three treatments.</p><p class="depth0"><em>(ii)</em> Indications for use. Treatment of joint dysfunction in horses due to noninfectious synovitis associated with equine osteoarthritis.</p><p class="depth0"><em>(iii)</em> Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[49 FR 45124, Nov. 15, 1984, as amended at 51 FR 11438, Apr. 3, 1986; 51 FR 25032, July 10, 1986; 53 FR 19773, May 31, 1988; 53 FR 22297, June 15, 1988; 56 FR 50814, Oct. 9, 1991; 57 FR 2837, Jan. 24, 1992; 59 FR 33198, June 28, 1994; 61 FR 59003, Nov. 20, 1996; 63 FR 59216, Nov. 3, 1998; 71 FR 1689, Jan. 11, 2006; 71 FR 39204, July 12, 2006; 75 FR 1274, Jan. 11, 2010; 75 FR 10167, Mar. 5, 2010; 78 FR 73698, Dec. 9, 2013; 79 FR 16189, Mar. 25, 2014; 79 FR 74020, Dec. 15, 2014; 80 FR 34279, June 16, 2015]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>. Code available <a href="#">on Github.</a></h5>
      </div>
    </div>
  </footer>
  </body>
</html>
